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Abstract
Background: Multidrug resistance (MDR) is a major factor which contributes to the failure of cancer chemotherapy, and
numerous efforts have been attempted to overcome MDR. To date, none of these attempts have yielded a tolerable and
effective therapy to reverse MDR; thus, identification of new agents would be useful both clinically and scientifically.
Methodology/Principal Findings: To identify small molecule compounds that can reverse chemoresistance, we developed
a 96-well plate high-throughput cell-based screening assay in a paclitaxel resistant ovarian cancer cell line. Coincubating
cells with a sublethal concentration of paclitaxel in combination with each of 2,000 small molecule compounds from the
National Cancer Institute Diversity Set Library, we identified a previously uncharacterized molecule, NSC23925, that inhibits
Pgp1 and reverses MDR1 (Pgp1) but does not inhibit MRP or BCRP-mediated MDR. The cytotoxic activity of NSC23925 was
further evaluated using a panel of cancer cell lines expressing Pgp1, MRP, and BCRP. We found that at a concentration of
.10 mM NSC23925 moderately inhibits the proliferation of both sensitive and resistant cell lines with almost equal activity,
but its inhibitory effect was not altered by co-incubation with the Pgp1 inhibitor, verapamil, suggesting that NSC23925 itself
is not a substrate of Pgp1. Additionally, NSC23925 increases the intracellular accumulation of Pgp1 substrates: calcein AM,
Rhodamine-123, paclitaxel, mitoxantrone, and doxorubicin. Interestingly, we further observed that, although NSC23925
directly inhibits the function of Pgp1 in a dose-dependent manner without altering the total expression level of Pgp1,
NSC23925 actually stimulates ATPase activity of Pgp, a phenomenon seen in other Pgp inhibitors.
Conclusions/Significance: The ability of NSC23925 to restore sensitivity to the cytotoxic effects of chemotherapy or to
prevent resistance could significantly benefit cancer patients.
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Introduction
Patients with advanced cancer are usually treated with
chemotherapy in order to extend life and palliate symptoms.
There is some improvement of responses seen in select cases by the
addition of immunotherapy or biological response modifiers [1].
Despite considerable advances in anticancer drug development,
with few exceptions, metastatic solid tumors in adults remain
largely incurable in part because of their eventual development of
resistance to chemotherapy [2]. The inevitable development of
multidrug resistant cancer cells during the course of treatment is a
major fundamental obstacle associated with cancer care. In these
cases, cancer cells become resistant to a variety of anticancer drugs
with different structures and mechanisms of action even if the
patient’s cancer has not been previously exposed to a particular
drug - a phenomenon known as cross-resistance. One type of cross
resistance known as multidrug resistance (MDR) has been studied
widely [2,3]. Other mechanisms of cross-resistance to chemother-
apy include alterations in pharmacokinetics, poor drug penetration
through the extracellular matrix, cell adhesion and increased
intratumoral hydrostatic pressure [3,4,5,6]. Both intrinsic and
acquired cellular drug resistance has been extensively studied using
cell lines induced to be resistant to chemotherapeutic drugs’
cytotoxic effects by prolonged culture in gradually increasing levels
of cytotoxic agents [7,8,9]. Although there are several different
intrinsic cellular mechanisms associated with the development of
MDR, an important molecular basis for MDR is overexpression of
plasma membrane glycoprotein (Pgp1) [3,10]. Pgp1 is the best
known mediator of MDR. Pgp1 is the gene product of
MDR1(ABCB1), a member of the ABC (ATP binding cassette)
superfamily of transporter proteins, and it acts as an energy-
dependent cancer drug efflux pump, preventing adequate
intracellular accumulation of a large number of cytotoxic drugs
including anthracyclines (doxorubicin,daunorubicin), vinca alka-
loids (vinblastine), taxanes (paclitaxel, docetaxel) and many others.
Innate or acquired expression of Pgp1 is therefore a major
problem in the treatment of patients with many types of cancer
[3,5].
Pgp1 (MDR1) expression, frequently detected in both solid and
hematologic malignancies, as well as in cancer stem cells, is a
marker of chemoresistance and decreased survival in leukemia,
lymphoma, osteosarcoma, small-cell lung cancer, ovarian cancer,
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chemotherapy regimens can achieve responses in patients with
solid tumors, recurrences are typical. When recurrent, tumors
often have acquired MDR, either by adaptation of previously
Pgp1-negative tumor cells or by selection for drug-resistant Pgp1
positive tumor cells [2,3]. Elimination of MDR cells during initial
treatment or at the time of recurrence is necessary to achieve
greater effect from chemotherapy.
A wide range of compounds that interact with Pgp1 and block
drug efflux have been reported to reverse the MDR phenotype
[10,11]. Unfortunately, these compounds are relatively nonspecific
and have low potency at doses patients can tolerate. With the
majority of these compounds, clinical toxicities associated with
their use at concentrations required to inhibit Pgp1 have
precluded their widespread use [10,12]. For example, verapamil,
a calcium channel blocker that also inhibits Pgp1, is associated
with cardiac toxicity at doses required to reverse MDR [13,14,15].
Full reversion of MDR by verapamil requires a concentration of
approximately 10 mM in most cell culture models; whereas plasma
levels above 1 mM results in complete heart block [10,16,17].
Cyclosporin A (CsA), besides reversing Pgp1, is also used clinically
for immunosuppression. However, at doses used to reverse MDR,
the immunosuppressive effect of CsA is harmful and, at higher
concentrations, CsA is nephrotoxic [10,17,18,19]. Another MDR
reversing agent, PSC833, has been reported to induce cerebellar
ataxia and hyperbilirubinemia [20,21]. Although CsA and PSC
833 both inhibit Pgp1, they have some modest inhibition of MRP1
[3,10]. The results from PSC 833 in phase III clinical trials showed
no survival benefits, consistent with of the other Pgp1 inhibitors
studied up to now [10,11]. The development of potent and
selective MDR inhibitors is an important unmet need for cancer
patients in the clinic.
Screening of chemical libraries for biologically active com-
pounds aimed at certain cellular targets is a powerful approach to
identify small molecules regulating cellular function that can be
useful as both research tools and therapeutic agents [22,23,24].
We screened 2000 small molecule compounds from the NCI
Diversity Set library to look for compounds that can reverse MDR
in a drug-resistant cell line. We observed that NSC23925 was the
most potent MDR reversing compound in this set. We showed
that NSC23925 can reverse drug-resistance for other MDR cell
lines, including ovarian, breast, colon cancer, and sarcoma cell
lines. NSC23925 was able to resensitize all of these cell lines to
paclitaxel, doxorubicin, vincristine, ET-743 and PM00104. We
anticipate that NSC23925 or a derivative of this compound may
have therapeutic value in the treatment of a variety of MDR
dependent cancers.
Materials and Methods
Drugs and chemicals
The Structural Diversity Set is a library of approximately 2,000
small molecules derived from the almost 140,000 compounds
available on plates through the National Cancer Institute (NCI).
These compounds are thought to have anti-tumor activity but
their functional data is limited. Detailed information on the
selection, structures, and activities of these diversity set compounds
can be found on the NCI Developmental Therapeutics Program
web site (http://dtp.nci.nih.gov). Paclitaxel, doxorubicin, and
cisplatin were obtained through unused residual clinical material
provided by the pharmacy at the Massachusetts General Hospital.
ET-743 (trabectidin, Yondelis) and PM00104 (Zalypsis) were
supplied by PharmaMar (Spain).
Cell Lines and antibodies
The paclitaxel-resistant U-2OSTR, SKOV-3TR, OVCAR8TR,
MCF-7TR and SW480TR lines as well as doxorubicin resistant
MCF-7DR and gemcitbine resistant OVCAR5GR cell lines were
established as previously reported [7,8,9,16]. The osteosarcoma
cell line U-2OS, KHOS, uterine sarcoma cell line MESSA and its
doxorubicin selected drug resistant cell line MESSA/Dx5, non-
small cell lung cancer cell line H-69 and it’s doxorubicin selected
drug resistant cell line H-69AR (overexpress MRP1) were obtained
from the ATCC (Rockville, MD). Dr. Efstathios Gonos (Institute
of Biological Research & Biotechnology, Athens, Greece) provided
the doxorubicin resistant U-2OS R2 (referred in the text below as
U-2OSDR), KHOS R2 cell lines [25]. Dr. Stephen. Howell (The
University of California Medical Center, San Diego) provided the
cisplatin-resistant ovarian cancer IGROV1cp and 2008cp70 cell
lines. Dr. Erasmus Schneider (Wadsworth Center, Albany)
provided the mitoxantrane resistant breast cancer MCF-7/MX
cell line. Dr. Katia Scotlandi (Institute Orthopedics Rizzoli, Italy)
provided ET-743 resistant TC-ET 6 nM and TC-ET 12 nM cell
lines.
The Pgp1 monoclonal antibody was purchased from Signet
(Dedham, MA). The monoclonal antibody to MRP1 and MTT
reagent were purchased from Sigma-Aldrich (St. Louis, MO). The
monoclonal antibody to BCRP antibody was purchased from
Chemicon (Temecula, CA).
Cell culture
All the cell lines were cultured in RPMI 1640 (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum, 100-
units/ml penicillin and 100 mg/ml streptomycin (Invitrogen). Cells
were incubated at 37uCi n5 %C O 2-95% air atmosphere and
passaged when near confluent monolayers were achieved using
2% trypsin-EDTA solution. Drug-resistant cell lines were
periodically cultured in the respective drug to confirm their drug
resistance characteristics.
High-throughput drug cytotoxicity assay
SKOV-3TR cells with chemotherapy drug paclitaxel were used
for initial high-throughput screening. SKOV-3TR showed 100-
fold more resistance to paclitaxel as compared with parental
sensitive cells and could grow in 0.3 mM concentration of
paclitaxel without showing toxicity. Screening conditions in
SKOV-3TR were optimized in 96-well plates for growth
conditions, small molecular compound and drug concentration
and assay times prior to screening. On day 1, SKOV-3TR cells
were seeded at 2610
4 cells/well on 96-well plates and labeled
with plate A, B, C and incubated for 24 hr at 37uC( F i g .1 ) .O n
day 2, plate A was added with 0.1 mM of paclitaxel, plate B was
added with different screening small molecular compound at
1 mM to each well without paclitaxel; Plate C was added with
both small molecular compound and paclitaxel at the same
concentration as described in plate A and B. From day 4 to day
6, fresh medium was replaced with necessity as described above
and evaluated for cytotoxicity under the microscope. On Day 6,
the number of viable cells was evaluated for cytotoxicity in any
wells under the microscope manually and final results
were determined via CellTiter 96HAQueous One Solution
Cell Cytotoxicity Assay (Promega, Madison, WI) by a
SPECTRAmaxH Microplate Spectrophotometer (Molecular
Devices, Sunnyvale, CA). Only the compounds at 1 mM showed
no cytotoxicity (without paclitaxel) to SKOV-3TR were selected
for further study.
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The general format was designed for screening the small
molecular compound library and identifying novel drug resistant
inhibitor. These include evaluation of each small molecular
compound through a well studied multidrug resistant cell line
SKOV-3TR. The experiments were conducted in two control
plates (A and B) and one experimental plate (C) to permit plate-to-
plate comparisons (Fig. 1). The control plates (plate A and B) were
used to evaluate cytotoxicity of paclitaxel and small molecular
compound itself, and to exclude compound that were lethal to the
cells in the absence of chemotherapy drug. Plate B was necessary
because the goal of this study was to identify small molecular
compound that can reverse drug resistance and not to determine
cell toxicity. Therefore, one plate (plate B) was given only small
molecular compound to confirm that the small molecule is not
lethal in the absence of paclitaxel (a positive result is cell survival);
Plate C was given both small molecular compound and 0.1 mM
paclitaxel. This is typically a sublethal dose of paclitaxel for the
SKOV-3TR cell line and a positive result would be cell death at 4–
6 days. Small molecular compound that were associated with cell
survival in plate A and plate B and death in plate C were identified
as ‘‘hits’’ and selected for further study. Once hits were identified,
we validated that the hits indeed could reverse drug resistance in
other drug resistant cell lines.
Cytotoxicity assay
Drug cytotoxicity was assessed in vitro using the MTT assay as
previously described [26,27]. Drugs at the concentrations utilized in
the MTT assay were performed in the absence of cells to verify no
change in absorbances. Experiments were performed in triplicate.
Duration of MDR reversal
The experiment was performed as previously described [28]. In
brief, 8610
5 SKOV-3TR cells/ml were incubated for 24 h with or
without NSC23925 or verapamil before being washed 3 times with
growth medium. The cells were then incubated for 4 days with
addition of varying concentrations of paclitaxel. Final results were
determined by MTT assay as described above.
Western blotting
Pgp1, MRP1, and BCRP proteins were analyzed in total cell
lysates. Total cell lysates were prepared, and Western blot analysis
was performed as previously described [8].
Drug efflux assay
The Vybrant
TM multi-drug resistance assay kit (Invitrogen/
Molecular Probes) was used to measure drug efflux properties of
different resistant cell lines. This assay utilizes the fluorogenic dye
calcein acetoxymethyl ester (calcein AM) as a substrate for efflux
activity of Pgp1 or other membrane pump ABC proteins. Calcein
AM is taken up by cells and hydrolyzed by cytoplasmic esterases to
fluorescent calcein. Calcein AM is well retained in the cytosol.
However, multidrug resistant cells expressing high levels of Pgp1
rapidly extrude non-fluorescent calcein AM from the plasma
membrane, reducing accumulation of fluorescent calcein in the
cytosol. Drug sensitive and resistant cells (50,000 cells per well)
were cultured in 96-well plate for 24 hours. Triplicated cultures of
cells were treated with NSC23925, verapamil for one hour and
then incubated in calcein AM in 100 ml total volume. After 30
minutes, the cells in plate were washed and centrifuged twice with
200 ml cold RPMI1640 culture medium, and cell fluorescence was
measured at a wavelength of 490 nm (A490) on a SPECTRAmaxH
Microplate Spectrofluorometer (Molecular Devices).
Fluorescence microscopy
For visualization of the effects of NSC23925 on the intracellular
retention of calcein AM, doxorubicin, and mitoxantrone, 10,000
resistant cells were seeded on to Lab-Tek 8-well chamber slides on
the day prior to the assay. Cells were then incubated with either,
0.25 mM calcein AM, 10 mM doxorubicin, or 10 mM mitoxan-
Figure 1. Flowchart of the screening small molecular compound to reverse drug resistance. For the screen, 2610
4 SKOV-3TR cells per well
in 96-well plates were added with different NCI Diversity Set library compound and paclitaxel as indicated. After culturing for 6 days, the number of
viable cells was analyzed using the CellTiter 96 AQueous One Solution Cell Cytotoxicity Assay and visualized under the microscope.
doi:10.1371/journal.pone.0007415.g001
NSC23925 and Drug Resistance
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7415trone either alone or in the presence of NSC23925 in RPMI 1640
media for one hour at 37uC. Images were acquired by Nikon
Eclipse Ti-U fluorescence microscope (Nikon Corp.) equipped
with a SPOT RT digital camera (Diagnostic Instruments, Inc.,
Sterling Heights, MI).
PGP-ATPase assay
The Pgp-Glo
TM Assay Systems (Promega) provide the necessary
reagents for performing luminescent P-glycoprotein (Pgp1)
ATPase assays. PGP-ATPase assay is a valuable screening tool
for determining if a drug interacts with Pgp1. The ATPase assay
provides a rapid, colorimetric, compound-independent measure of
the concentration-dependence of any interaction of a drug with
Ppg1. If a drug does not stimulate Pgp1-ATPase activity, the assay
can still determine if the drug interacts with Pgp1 as an inhibitor of
the ATPase activity stimulated by a known substrate, such as
verapamil. The effect of NSC23925 on the ATPase activity of
Pgp1 was measured according to the manufacturer’s protocol.
Statistical data analysis
Values shows are representative of triplicate determinations in
two or more experiments. Treatment effects were evaluated using
a two-sided Student’s t test (GraphPadPRISMH 4 software,
GraphPad Software, San Diego, CA). Errors are SD of averaged
results and P,0.05 values were accepted as a significant difference
between means.
Results
Establishment of cell based high-throughput screening
of drug resistance inhibitors
To identify candidate small molecule compounds that can reverse
drug resistance in MDR cell lines, we designed an assay to detect
reconstitution of paclitaxel cytotoxicity in a Pgp1-expressing, multidrug
resistanthumanovariancancercelllineSKOV-3TR.0. 1mMpaclitaxel
was determined to be the concentration of paclitaxel that is lethal to
drug sensitive SKOV-3 cells, but does not affect the growth of drug
resistant SKOV-3TR cells. Cells were arrayed in 96-well plates and
each well was incubated for six days in optimized culture conditions
with 0.1 mM paclitaxel, 1 mM library compound, or both 0.1 mM
paclitaxel and 1 mM library compound (Fig. 1). Cell growth was
assessed daily for six days (see Materials and Methods section).
Identification of small molecule compound, NSC23925,
as a small molecule compound that reverses multiple
drug resistance in human cancer cell lines
After screening ,2,000 small molecule compounds in the NCI
Diversity Set library for synergistic cytotoxicity with paclitaxel,
Figure 2. Chemical structure of NSC23925 and reverse paclitaxel resistance by NSC23925. A: Structure of NSC23925. B: NSC23925 in
combination with 0.1 mM paclitaxel induces significantly cell death in SKOV-3TR.
doi:10.1371/journal.pone.0007415.g002
NSC23925 and Drug Resistance
PLoS ONE | www.plosone.org 4 October 2009 | Volume 4 | Issue 10 | e7415Figure 3. Effect of NSC23925 to reverse drug resistance in MDR cell lines. Cells were treated with the paclitaxel and NSC23925 in RPMI1640
complete media at the indicated concentrations. The relative sensitivity of each line to paclitaxe was determined by MTT analysis 6 days
posttreatment. A: Reversal of paclitaxel resistance by NSC23925 in SKOV-3TR cells. B: Reversal of paclitaxel resistance by NSC23925 in OVCAR8TR cells.
doi:10.1371/journal.pone.0007415.g003
Table 1. Effect of NSC23925 Reversing Drug Resistance in Multidrug Resistant Cell Lines.
SKOV-3TRIC50 (mM) OVCAR8TR IC50 (mM) KHOSR2IC50(mM)
Paclitaxel 0.31060.021 0.3460.032 0.2160.023
Add NSC23925 0.1 mM 0.30260.056 (1.03) 0.12760.027 (2.7) 0.1660.016 (1.3)
Add NSC23925 0.5 mM 0.13260.047 (2.4) 0.07260.046 (4.7) 0.1260.032 (1.8)
Add NSC23925 1 mM 0.03760.028 (8.4) 0.02860.047 (12.1) 0.0660.020 (3.5)
Doxorubicin 22.3460.2 27.62460.256 10.3460.566
Add NSC23925 0.1 mM 16.5260.21 (1.4) 12.3560.36 (2.3) 7.36460.336 (1.4)
Add NSC23925 0.5 mM 6.7860.16 (3.3) 5.20060.471 (5.3) 1.20560.461 (8.6)
Add NSC23925 1 mM 1.9460.22 (11.5) 1.21660.122 (23) 0.29260.210 (35)
ET-743 0.00460.002 0.00660.002 0.17560.025
Add NSC23925 0.1 mM 0.00560.002 (0.8) 0.00560.001 (1.2) 0.14560.045 (1.2)
Add NSC23925 0.5 mM 0.00460.001 (1) 0.00560.001 (1.2) 0.08360.039 (2.1)
Add NSC23925 1 mM 0.00460.001 (1) 0.007+0.002 (0.9) 0.05460.034 (3.2)
PM00104 0.00660.001 0.00860.002 0.14360.045
Add NSC23925 0.1 mM 0.00560.002 (1.2) 0.00860.002 (1) 0.11360.038 (1.3)
Add NSC23925 0.5 mM 0.00760.001 (0.9 0.00660.002 (1.3) 0.02660.014 (5.5)
Add NSC23925 1 mM 0.00560.002 (1.2) 0.00560.002 (1.6) 0.00860.016 (17.9)
IC50 is the concentration of drug (mM) that produced 50% inhibition of cell growth.
Results were calculated from one experiment with triplicate wells. 6 reflect SDEV (SD).
Number in the parentheses represent fold-reversal of drug resistance.
doi:10.1371/journal.pone.0007415.t001
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paclitaxel) to SKOV-3TR at a concentration of 1 mM. Two
compounds, NSC23925 and NSC77037, were identified as the
agents with highest activity to reverse drug resistance without
cytotoxicity by itself (Fig. 2A). NSC77037(Tetrandrine), a bis-
benzylisoquinoline alkaloid compound, has been shown to reverse
doxorubicin resistance in a breast cancer cell line both in vitro and
in vivo [29,30,31]. In contrast, there are no prior reports
describing NSC23925 (2-(4-methoxyphenyl)-4-quinolinyl)(2-piper-
idinyl) methanol) or its activity for reversing drug resistance. When
combined with 1 mM NSC23925, 0.1 mM paclitaxel induces
significant cell death in SKOV-3TR,which grows well in either
0.1 mM paclitaxel or 1 mM NSC23925 alone (Fig. 2B).
Modulation of drug resistance in MDR cell lines
To determine whether NSC23925 is able to reverse drug
resistance in other cancer cell lines, we evaluated the effects of
NSC23925 on several MDR cell lines using a variety of anti-
cancer agents. We observed that NSC23925 reverses chemoresis-
tance in a wide variety of tumor types where MDR1 is highly
expressed; these tumor types include the ovarian cancer cell lines
SKOV-3TR and OVCAR8TR, breast cancer cell line MCF-7TR,
and sarcoma cell lines MESSA/Dx5, KHOS R2, and U-2OSDR
(representative data from SKOV-3TR, OVCAR8TR, and KHOS
R2 shown in Table 1). Maximal reversal of MDR was typically
seen in NSC23925 doses between 0.5 and 1 mM (Fig. 3).
NSC23925 was highly active across the panel of cell lines and
demonstrated significant reversal of chemoresistance when used in
conjunction with paclitaxel, docetaxel, doxorubicin, daunorubicin,
gemcitabine, vincristine, ET-743, or PM00104 (Table 2). The
potency of NSC23925 was 10 to 50 fold greater than that of
verapamil or CsA. Moreover, the presence of ,5-10 mMo f
NSC23925 alone had no cytotoxic effect in the parental cell lines
SKOV-3 and OVCAR8 which lack expression of Pgp1 (Fig. 4A
and 4B). Importantly, NSC23925 did not alter the cytotoxicity of
cisplatin and methotrexate, both agents known to be unaffected by
MDR1 mechanisms (Table 2). These results suggest that reversal
of resistance was mostly attributable to the inhibition of Pgp1.
Furthermore, we tested other cell lines with non-Pgp1 mediated
MDR mechanisms (H69/AR cells that express MRP1, but not
Pgp1, and MCF-7 MX cells that express BCRP, but not Pgp1) to
evaluate the specificity of NSC23925. We observed that
NSC23925 was unable to reverse drug resistance in these non-
Pgp1 expressing drug resistant cell lines, suggesting that
NSC23925 activity is specific for Pgp1.
NSC23925 itself is not a Pgp1 substrate
Although NSC23925 reversed Pgp1 mediated MDR in the
nanomolar concentration range, NSC23925 was not cytotoxic by
itself at doses up to 10 mM in both sensitive and resistant cell lines.
At high concentrations, NSC23925 by itself is equally inhibitory
on the proliferation of both SKOV-3 and SKOV-3TR and for
OVCAR8 and OVCAR8TR cell lines in a dose-dependent manner
(Fig. 4A and 4B). IC50s were similar in matched cell lines that did
and did not express Pgp1. The IC50 for NSC23925 is 8 mMi n
SKOV-3/SKOV-3TR and 25 mM in OVCAR8/OVCAR8TR cell
lines, whereas the mean concentration of NSC23925 required for
maximal reversal of resistance in SKOV-3TR or OVCAR8TR to
cytotoxic drugs is 0.5 mMt o1 mM (Fig. 3A and 3B). Thus,
NSC23925 is cytotoxic at concentrations 10 to 50 fold greater
than those required for maximal reversal of drug resistance. This
indicates that overexpression of Pgp1 does not confer resistance to
the cytotoxic effects of single agent NSC23925. These results also
suggest that compounds like NSC23925 are not Pgp1 transport
substrates [28,32,33]. To confirm this, we determined the effect of
the Pgp1 inhibitor, verapamil, on NSC23925 sensitivity in Pgp1-
overexpressing SKOV-3TR cells. As expected, verapamil did not
influence the cytotoxic effect of NSC23925 in SKOV-3TR cells
(Fig. 5A). Similar results were found in OVCAR8TR (data not
shown). This data collectively demonstrates that NSC23925 itself
is not a substrate of Pgp1, and Pgp1 does not confer resistance to
the cytotoxic effects of NSC23925 in tumor cells. Also, NSC23925
is not subject to cross resistance with classical cytotoxic agents such
as paclitaxel or doxorubicin. These results are of clinical
significance because they suggest that NSC23925 may be a good
Figure 4. Nonspecific toxicity of NSC23925 on SKOV3 vs SKOV-
3TR and OVCAR8 vs OVCAR8TR. Cells were treated with the NSC23925
in RPMI1640 complete media at the indicated concentrations. The relative
sensitivity of each line to NSC23925 was determined by MTT assay. A:
Nonspecific toxicity of NSC23925 on SKOV3 vs SKOV-3TR and OVCAR8 vs
OVCAR8TR. B: Nonspecific toxicity of NSC23925 on OVCAR8 vs OVCAR8TR.
doi:10.1371/journal.pone.0007415.g004
Table 2. Reverse Drug Resistance by NSC23925
Decreased drug resistance No effect
Paclitaxel Cisplatin
Docetaxel Carboplatin
Doxorubicin Topotecan
Vincristine Methotrexate
Daunorubicin
Vincristine
Gemcitabine
ET-743
PM00104
doi:10.1371/journal.pone.0007415.t002
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Duration of NSC23925 activity
The ability of NSC23925 to inhibit Pgp1 mediated efflux and its
duration of action were investigated using two MDR substrates,
paclitaxel, doxorubicin, and two MDR cell lines SKOV-3TR and
OVCAR8TR. Weobserved that NSC23925 inhibits the efflux of both
paclitaxel and doxorubicin from MDR cells and that the inhibitory
effects of NSC23925 remains even when it was washed out from the
efflux medium after overnight exposure (1 mM) (Fig. 5B). NSC23925
was effective at inhibiting Pgp1 mediated transport for at least 4 days
after wash-out. In comparison, verapamil even after exposure to very
high concentration (20 mM), displayed only a short duration (24 h) of
inhibition (Fig. 5B). Similar results were obtained in OVCAR8TR
cells (data not shown).
NSC23925 modulates pgp1-mediated uptake and efflux
of calcein AM and other Pgp1 substrates
Reversal of MDR is usually manifested as an increased
intracellular accumulation of chemotherapeutics, which can be
achieved by disturbing Pgp1-mediated drug uptake and efflux.
Therefore, we examined the effect of NSC23925 on the uptake
and efflux of several substrates of Pgp1 (calcein AM, for example)
in SKOV-3TR and OVCAR8TR. NSC23925 was shown to
increase intracellular accumulation of calcein AM in these cell
lines in a dose-dependent manner as determined by both image
analysis (Fig. 6A and 6C) and by microplate spectrofluorometer
analysis (Fig. 6B and 6D). NSC23925 has a prominent effect on
the accumulation of calcein AM in these cells starting at a
concentration as low as 1 nM. Half-maximal reversal of
accumulation deficit was observed at 100 nM and near maximal
at 500 nM. The potency of NSC23925 was significantly greater
than that observed for verapamil and CsA (Fig. 6). In the control
parental drug-sensitive cell lines SKOV-3 and OVCAR8, which
do not overexpress Pgp1, NSC23925 had no evident effect on
accumulation of calcein AM (Fig. 6A and 6B). To confirm that
NSC23925 inhibition of Pgp1-mediated efflux was not specific for
only calcein AM, we further evaluated NSC23925 inhibition of
efflux with other Pgp substrates including Rhodamine 123,
mitoxantrone, dioc 2 and doxorubicin. The fluorescence levels
of these agents were monitored to determine cellular accumula-
tion. We observed that NSC23925 inhibited the efflux of these
Pgp1 substrates from SKOV-3TR (Fig. 7). Flow cytometric analysis
further confirmed that NSC23925 treatment increases the
accumulation of doxorubicin in SKOV-3TR and KHOSR2 cells
(Fig. 8).
NSC23925 stimulates Pgp1 ATPase activity, but does not
affect Pgp1 expression
The increased accumulation of intracellular drug may be a
result of decreased expression of Pgp1 or decreased function of
Pgp1. Pgp1 has an ATP-binding region that is essential for
substrate transport, and the hydrolysis of ATP by Pgp1 ATPase is
critical for restoring the transporter to its active conformational
state. Thus, monitoring ATPase activity in cell membrane
preparations or in purified membrane proteins allows for
identification of those compounds that interact with the drug
Figure 5. Effect of verapamil on NSC23925 sensitivity in Pgp1-overexpressing cells and persistence of NSC23925 activity. A: Effect of
verapamil on NSC23925 sensitivity in SKOV-3TR cells. SKOV-3TR cells were treated with different concentration of NSC23925 alone or in combination
with verapamil for 72 hours. Drug cytotoxicity was determined by MTT assay as described in the Materials and Methods. B: Persistence of NSC23925
reverses paclitaxel resistance in SKOV-3TR cells after incubation and washout of NSC23925 or verapamil.
doi:10.1371/journal.pone.0007415.g005
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hydrolysis activity, and a variety of Pgp1 inhibitors, as well as Pgp1
substrates, can stimulate ATPase activity [32,33,34,35]. In the
ATPase activity assay, a test molecule is concluded to interact
specifically with Pgp1 if it significantly modulates ATPase
activities, at any one of the concentrations (0.05 to 50 mM).
Utilizing this method, we examined the effect of NSC23925 on
both the expression and function of Pgp1. We observe that
NSC23925 significantly increased the ATPase activity in purified
recombinant human Pgp1 membrane protein and this stimulation
was dose-dependent (Fig. 9). However, the expression level of
Pgp1 was not affected by different treatments with the addition of
NSC23925 (up to 10 mM for 48 h) (Fig. 9E). These results suggest
that NSC23925 stimulates Pgp1 ATPase activity by directly
interacting with Pgp1.
Discussion
In this study, we screened 2,000 small molecule compounds in
the NCI Structural Diversity Set to identify agents capable of
reversing multidrug resistance in MDR cell lines. The present
study extends the previous techniques such as flow cytometric
analysis, dye efflux assay, and bioinformatic approaches to find
novel MDR inhibitors by directly reversing MDR in a cell-based
high-throughput assay [24,36,37]. The cell-based screening
technique has the advantage of unbiased testing of a large number
of small-molecule compounds to detect reversal of drug resistance.
This approach identified a small molecular compound,
NSC23925, as a novel agent that reverses MDR in Pgp1
overexpressing cell lines. NSC23925 is a novel methoxyphenyl
piperidinyl compound (http://pubchem.ncbi.nlm.nih.gov/) with
molecular weight 348. Unlike NSC77037/tetrandrine, informa-
tion about NSC23925 pharmacological action is lacking. There is
no prior report describing the action of NSC23925 on reversing
chemoresistance in cancer. We demonstrated such reversal of
MDR in cell lines derived from ovarian cancer, breast cancer,
colon cancer, and sarcoma tumors. We observed reversal of MDR
for paclitaxel, doxorubicin, ET-743, and other anti-cancer agents.
In multidrug resistant cell lines which highly express MDR1
(Pgp1 protein), Pgp1 functions as an energy-dependent membrane
transporter that rapidly extrudes chemotherapeutic drugs from
cells, and therefore prevents the drugs from exerting cytotoxic
effects. Many studies with multidrug resistant cells correlated
resistance to reduced accumulation of drugs within the cells due to
increased efflux or decreased influx by Pgp1[3,7,10]. As Pgp1 is an
ATP-dependent transport protein, agents that inhibit ATP-
dependent drug transport should inhibit the efflux of drugs from
resistant cells and increase intracellular accumulation. In this
study, we observed that NSC23925 increased the intracellular
accumulation of the Pgp1 substrates: paclitaxel, calcein-AM,
rhodamine-123 (Rh-123) and doxorubicin. We show that
NSC23925 stimulates ATPase activity in a dose-dependent
Figure 6. Calcein AM efflux from treated SKOV-3 and SKOV-3TR cells. The Calcein-AM assay was optimized and performed using the Vybrant
Multidrug Resistance kit and SKOV-3TR cells. Cells were seeded at 50,000 cells/well (100 ml of culture medium) in 96-well plate and incubated for 24 h.
SKOV-3TR cells in triplicate were treated with NSC23925, verapamil for one hour and then incubated in calcein AM for 30 min. The cell fluorescence
images were acquired by a fluorescence microscope (A, C) and quantities of fluorescence were measured in a SPECTRAmax Microplate
Spectrofluorometer (B, D). The data were representative of one of three independent experiments. *, P,0.001.
doi:10.1371/journal.pone.0007415.g006
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Although ATPase activity is closely associated with the function of
Pgp1, an increase in ATPase activity does not necessarily lead to
an enhancement of Pgp1 function. Previous reports have
demonstrated that certain chemosensitizers enhance the ATPase
activity of Pgp [33,40,41,42] For example, verapamil is another
example of a Pgp1 inhibitor, stimulates the ATPase activity of
Pgp1, and inhibits Pgp1 function [33]. The MDR inhibi-
tor,5,7,30,40,50-pentamethoxyflavone (PMF) stimulates the
ATPase activity in a concentration dependent manner [42].
Gefitinib, an EGFR tyrosine kinase inhibitor, also stimulates
ATPase activity of Pgp and directly inhibits the function of Pgp in
Figure 7. NSC23925 increases Pgp1 substrates accumulation in SKOV-3TR. Images of SKOV-3TR cells incubated with various fluorescent
substrates of Pgp1 in the presence (bottom panel) and absence (top panel) of NSC23925. For visualization of effects of NSC23925 on the intracellular
retention of rhodamine 123, mitoxantrone, Dioc2, doxorobucin, and calcein AM, 10,000 resistant cells were seeded on to Lab-Tek 8-well chamber
slides on the day prior to the assay. SKOV-3TR cells were then incubated with either 1 mM rhodamine 123, 10 mM mitoxantrone, 0.1 mM Dioc2, 10 mM
doxorubicin or 0.25 mM calcein AM either alone or in the presence of NSC23925 in RPMI 1640 media for one hour at 37uC. Image were acquired a
Nikon Eclipse Ti-U fluorescence microscope (Nikon Corp.) equipped with a SPOT RT digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI).
doi:10.1371/journal.pone.0007415.g007
Figure 8. Intracellular retention of doxorubicin from multidrug resistant SKOV-3TR and KHOSR2 cells in the presence of 5 mM
doxorubicin with or without treatment of NSC23925 (0.5 mM). Cells were treated for 1 hour before the flow cytometry analysis.
doi:10.1371/journal.pone.0007415.g008
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(ABCG2) inhibitor is 6-prenylchrysin, a flavonoid compound that
also inhibits MXR function by stimulating the ATPase activity of
MXR [32]. However, the molecular mechanisms of enhancement
of Pgp ATPase activity by these Pgp inhibitors are unknown
[44,45]. Like these Pgp or MXR inhibitors, the mechanism of how
NSC23925 stimulates Pgp ATPase activity but inhibits the
function of Pgp deserves further investigation.
Our core observations are that (1) the function of Pgp1 mainly
functions to efflux drugs out of MDR tumor cells, (2) NSC23925
was observed to inhibit the efflux of substrates of Pgp1, such as
paclitaxel and doxorubicin, (3) NSC23925 at 10 mM for 48 hours
does not inhibit the expression level of Pgp1, and (4) NSC23925
stimulates Pgp ATPase activity. Taken together, these observations
support the hypothesis that NSC23925 reverses MDR in tumor
cells by uncoupling Pgp ATPase activity from the drug efflux
activity of Pgp1.
The potency was confirmed by several assays (including
cytotoxic drug sensitivity MTT assay, enhancement of drug
uptake Vybrant
TM multidrug resistance assay, inhibition of drug
efflux assay, and mechanisms of NSC23925 inhibition by Pgp-Glo
assay) using a panel of multidrug resistant cell lines with different
degrees of drug resistance and Pgp1 expression. In these assays,
full to partial reversal of resistance in several MDR cell lines to
several major classes of chemotherapy drugs was achieved in the
presence of 10 to 2,000 nM NSC23925. Direct comparison with
several modulators such as verapamil and CsA in different assays
demonstrated that NSC23925 is the most potent among the three
Figure 9. Stimulation of Pgp1 ATPase activity by NSC23925 as compared with verapamil. Untreated, 100 mMN a 3VO4, 100 mM verapamil
and 10 mM NSC23925 -treated Pgp1 reactions were performed according to the manufacturer’s protocol. Luminescence was read on a BMG LABTECH
Polarstar Optima Luminometer. The decrease in luminescence of untreated samples compared to samples plus Na3VO4 (ARLUbasal) represents basal
Pgp1 ATPase activity. The decrease in luminescence of verapamil or NSC23925 treated samples represent Pgp1 ATPase activity. A: Decrease in
luminescence of NSC23925 treated sample as compared with Na3VO4 or Verapamil treated sample. B: Replotted the stimulation of Pgp1 ATPase
activity by verapamil and NSC23925. C and D: Dose dependence of verapamil (C) and NSC23925 (D) stimulation of Pgp1 ATPase activity. The data
were representative of one of three independent experiments. *, P,0.001. E: Effect of NSC23925 on expression of Pgp1 in paclitaxel resistant cells.
The paclitaxel resistant cell line SKOV-3TR were treated with different concentration of NSC23925 for 48 h. Equal amounts (20 mg protein) of total cell
lysates were used for each sample. Pgp1 expression was determined by Western blot as described in the Materials and Methods.
doi:10.1371/journal.pone.0007415.g009
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and 50-fold more potent than CsA in the same concentration.
Our study shows that reversal of MDR by NSC23925 was
through selective and potent inhibition of Pgp1 function. For
example, in contrast to the modulatory activity in the resistant cell
lines, NSC23925 had no significant effect on cytotoxic drug
activity in non-Pgp1 expressing parental cell lines nor did it affect
the cytotoxicity of non-Pgp1 substrates such as cisplatin and
methotrexate. Moreover, the concentration of NSC23925 re-
quired to fully reverse drug resistance in vitro was 10 to 20 fold
lower than the concentration at which any toxicity (IC50) was
observed in the cell lines. Further confirmation of selectivity of
NSC23925for Pgp1 was provided by the fact that the NSC23925,
even at very high concentrations (50 mM), did not inhibit MRP1
or BCRP function. These findings provide support for further
development of NSC23925 or its derivates as candidate inhibitors
of MDR in cancer treatment. Such efforts can further our
understanding of the molecular mechanisms of drug resistance.
Acknowledgments
We thank Drs. Doug Smallwood and Robert J. Schultz from the NCI
Developmental Therapeutics Program for providing the Diversity Set
Library.
Author Contributions
Conceived and designed the experiments: ZD FJH. Performed the
experiments: ZD EC. Analyzed the data: ZD EC FJH. Contributed
reagents/materials/analysis tools: ZD FJH. Wrote the paper: ZD EC FJH.
References
1. Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies
in ovarian cancer. Nat Rev Cancer 9: 167–181.
2. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev
Cancer 5: 275–284.
3. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of
ATP-dependent transporters. Nat Rev Cancer 2: 48–58.
4. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel
resistance: molecular mechanisms and pharmacologic manipulation. Curr
Cancer Drug Targets 3: 1–19.
5. Mellor HR, Callaghan R (2008) Resistance to chemotherapy in cancer: a
complex and integrated cellular response. Pharmacology 81: 275–300.
6. Mimeault M, Batra SK (2006) Recent advances on multiple tumorigenic
cascades involved in prostatic cancer progression and targeting therapies.
Carcinogenesis 27: 1–22.
7. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV (2005) Description of
paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
Cancer Chemother Pharmacol 55: 277–285.
8. Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, et al. (2009) Diverse
cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell
lines. Cancer Chemother Pharmacol 63: 1121–1129.
9. Lamendola DE, Duan Z, Yusuf RZ, Seiden MV (2003) Molecular description of
evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell
line. Cancer Res 63: 2200–2205.
10. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006)
Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219–234.
11. Kaye SB (2008) Reversal of drug resistance in ovarian cancer: where do we go
from here? J Clin Oncol 26: 2616–2618.
12. Sikic BI (1997) Pharmacologic approaches to reversing multidrug resistance.
Semin Hematol 34: 40–47.
13. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, et al.
(2000) Verapamil increases the survival of patients with anthracycline-resistant
metastatic breast carcinoma. Ann Oncol 11: 1471–1476.
14. Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, et al. (1993)
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a
randomised study. Br J Cancer 67: 1031–1035.
15. Ferry DR, Traunecker H, Kerr DJ (1996) Clinical trials of P-glycoprotein
reversal in solid tumours. Eur J Cancer 32A: 1070–1081.
16. Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV (1999) TRAG-3, a
novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229:
75–81.
17. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer.
Mechanisms, reversal using modulators of MDR and the role of MDR
modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm
Sci 11: 265–283.
18. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, et al. (2004) Dose
escalation studies of cytarabine, daunorubicin, and etoposide with and without
multidrug resistance modulation with PSC-833 in untreated adults with acute
myeloid leukemia younger than 60 years: final induction results of Cancer and
Leukemia Group B Study 9621. J Clin Oncol 22: 4290–4301.
19. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, et al. (2001)
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone
(VAD) compared with VAD alone in patients with advanced refractory multiple
myeloma: an EORTC-HOVON randomized phase III study (06914).
Br J Haematol 115: 895–902.
20. Twentyman PR, Bleehen NM (1991) Resistance modification by PSC-833, a
novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer 27:
1639–1642.
21. te Boekhorst PA, van Kapel J, Schoester M, Sonneveld P (1992) Reversal of
typical multidrug resistance by cyclosporin and its non-immunosuppressive
analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1
phenotype. Cancer Chemother Pharmacol 30: 238–242.
22. Caldwell JS (2007) Cancer cell-based genomic and small molecule screens. Adv
Cancer Res 96: 145–173.
23. Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, et al. (2007) 8-benzyl-
4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel
janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian
cancer cells. Mol Pharmacol 72: 1137–1145.
24. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, et al. (2004)
Predicting drug sensitivity and resistance: profiling ABC transporter genes in
cancer cells. Cancer Cell 6: 129–137.
25. Lourda M, Trougakos IP, Gonos ES (2007) Development of resistance to
chemotherapeutic drugs in human osteosarcoma cell lines largely depends on
up-regulation of Clusterin/Apolipoprotein J. Int J Cancer 120: 611–622.
26. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987)
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment
of chemosensitivity testing. Cancer Res 47: 936–942.
27. Ulukaya E, Colakogullari M, Wood EJ (2004) Interference by anti-cancer
chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemo-
therapy 50: 43–50.
28. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, et al. (1996) Reversal
of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldiben-
zosuberane modulator, LY335979. Cancer Res 56: 4171–4179.
29. Dai CL, Xiong HY, Tang LF, Zhang X, Liang YJ, et al. (2007) Tetrandrine
achieved plasma concentrations capable of reversing MDR in vitro and had no
apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother
Pharmacol 60: 741–750.
30. Iorns E, Lord CJ, Ashworth A (2009) Parallel RNAi and compound screens
identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J
417: 361–370.
31. Zhu X, Sui M, Fan W (2005) In vitro and in vivo characterizations of tetrandrine
on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Anticancer Res 25: 1953–1962.
32. Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S, et al.
(2005) Flavonoid structure-activity studies identify 6-prenylchrysin and tecto-
chrysin as potent and specific inhibitors of breast cancer resistance protein
ABCG2. Cancer Res 65: 4852–4860.
33. Garrigues A, Nugier J, Orlowski S, Ezan E (2002) A high-throughput screening
microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem
305: 106–114.
34. Litman T, Skovsgaard T, Stein WD (2003) Pumping of drugs by P-glycoprotein:
a two-step process? J Pharmacol Exp Ther 307: 846–853.
35. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al. (1999)
Biochemical, cellular, and pharmacological aspects of the multidrug transporter.
Annu Rev Pharmacol Toxicol 39: 361–398.
36. Wang EJ, Casciano CN, Clement RP, Johnson WW (2000) In vitro flow
cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug
Metab Dispos 28: 522–528.
37. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J (2003) Comparison of in
vitro P-glycoprotein screening assays: recommendations for their use in drug
discovery. J Med Chem 46: 1716–1725.
38. Rosenberg MF, Velarde G, Ford RC, Martin C, Berridge G, et al. (2001)
Repacking of the transmembrane domains of P-glycoprotein during the
transport ATPase cycle. EMBO J 20: 5615–5625.
39. Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance
transporters. Nature 446: 749–757.
40. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, et al.
(1992) Partial purification and reconstitution of the human multidrug-resistance
pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad
Sci U S A 89: 8472–8476.
41. Hamada H, Tsuruo T (1988) Characterization of the ATPase activity of the Mr
170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with
multidrug resistance in K562/ADM cells. Cancer Res 48: 4926–4932.
NSC23925 and Drug Resistance
PLoS ONE | www.plosone.org 11 October 2009 | Volume 4 | Issue 10 | e741542. Choi CH, Kim JH, Kim SH (2004) Reversal of P-glycoprotein-mediated MDR
by 5,7,39,49,59-pentamethoxyflavone and SAR. Biochem Biophys Res Commun
320: 672–679.
43. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, et al. (2005) Gefitinib, an
EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein
in multidrug resistant cancer cells. Lung Cancer 49: 337–343.
44. Scarborough GA (2003) Rethinking the P-type ATPase problem. Trends
Biochem Sci 28: 581–584.
45. Scarborough GA (2002) Molecular mechanism of the P-type ATPases.
J Bioenerg Biomembr 34: 235–250.
NSC23925 and Drug Resistance
PLoS ONE | www.plosone.org 12 October 2009 | Volume 4 | Issue 10 | e7415